Indicators
Indicators
Value
Direction
MACD(12,26,9)
-1.451
Neutral
RSI(14)
50.355
Neutral
STOCH(KDJ)(9,3,3)
51.265
Neutral
ATR(14)
8.986
High Vlolatility
CCI(14)
9.891
Neutral
Williams %R
45.691
Neutral
TRIX(12,20)
0.001
Sell
StochRSI(14)
88.789
Buy
Search
Biogen Inc
BIIBAdd to Watchlist
202.190USD
+1.570+0.78%
Close 07-24 16:00（ET）Quotes delayed by 15 min
29.84BMarket Cap
21.63P/E TTM
View Detailed Chart
TradingKey ChartIntraday
1m
30m
1h
D
W
M
D
Today
+0.78%
5 Days
-1.84%
1 Month
+0.11%
6 Months
+17.83%
Year to Date
+14.89%
1 Year
+53.73%
Key Figures
202.240Open
203.300High
596.37KVolume
21.63P/E TTM
12.28P/E Dynamic
--Dividend TTM
0.40%Turnover Ratio
200.620Prev. Close
200.035Low
99.34MTurnover
18.28P/E Static
1.60P/B
0.00%Div Yield TTM
4.77%ROA
205.97052wk High
0.73Volume Ratio
1.63BNet Profit
147.60MShares
9.3497EPS TTM
0.20Beta
7.70%ROE
121.05052wk Low
1.63%Amplitude
67.81%Gross Margin
29.84BMarket Cap
-3.42Reward/Risk
2.09%Risk Rate
TradingKey Stock Score of Biogen Inc
Currency: USD Updated: 2026-07-24Key Insights
Biogen Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 12 out of 155 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 227.44.In the medium term, the stock price is expected to trend up.Despite a weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Biogen Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
39°C
Very Low
Very High
Positive
Biogen Inc Highlights
StrengthsRisks
Biogen Inc. is a global biopharmaceutical company. The Company is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. It also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).
Fairly Valued
The company’s latest PE is 21.63, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 144.76M shares, decreasing 2.68% quarter-over-quarter.
Held by John Hussman
Star Investor John Hussman holds 5.84K shares of this stock.
Analyst Rating
Based on
37
analysts
Buy
Current Rating
228.772
Target Price
+14.03%
Upside Space
Biogen Inc News
More news coming soon, stay tuned...
Earnings Forecast
Analyst Rating
Based on
37
analysts
Buy
Current Rating
228.772
Target Price
+14.03%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
160
Total
6
Median
9
Average
Company name
Ratings
Analysts
Biogen Inc
BIIB
37
Amgen Inc
AMGN
38
Eli Lilly and Co
LLY
34
AbbVie Inc
ABBV
34
Pfizer Inc
PFE
32
Merck & Co Inc
MRK
32
1
2
3
...
32
Indicators
Moving Average
Indicators
Value
Direction
MA5
200.732
Buy
MA10
201.679
Buy
MA20
205.197
Sell
MA50
199.429
Buy
MA100
192.141
Buy
MA200
181.939
Buy
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Biogen Inc Info
Biogen Inc. is a global biopharmaceutical company. The Company is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. It also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).
Ticker SymbolBIIB
CompanyBiogen Inc
CEOViehbacher (Christopher A)
Websitehttps://www.biogen.com/
Shareholders
Related Instruments
+0.88%
+1.60%
+0.43%
+0.90%
+0.46%
-0.72%
+1.22%
+1.25%
-1.18%
-0.12%
+0.94%
+0.90%
+1.20%
-0.02%
+2.04%
0.00%
+0.63%
-0.69%
+2.59%
+0.89%Popular Instruments
51900.000
+176.000 (+0.34%)
28150.400
-427.600 (-1.50%)
7408.100
-11.800 (-0.16%)
14948.000
-153.000 (-1.01%)
64219.000
-1152.000 (-1.76%)
6264.500
+48.800 (+0.79%)
90.043
-2.069 (-2.25%)
333.020
+11.360 (+3.53%)
206.840
-1.920 (-0.92%)
4052.350
+2.980 (+0.07%)
FAQs
What is the current price of Biogen Inc (BIIB)?
The current price of Biogen Inc (BIIB) is 202.19.
What is the symbol of Biogen Inc?
The ticker symbol of Biogen Inc is BIIB.
What is the 52-week high of Biogen Inc?
The 52-week high of Biogen Inc is 205.97.
What is the 52-week low of Biogen Inc?
The 52-week low of Biogen Inc is 121.05.
What is the market capitalization of Biogen Inc?
The market capitalization of Biogen Inc is 29.84B.
Is Biogen Inc (BIIB) currently rated as Buy, Hold, or Sell?
According to analysts, Biogen Inc (BIIB) has an overall rating of Buy, with a price target of 228.77.
What is the Earnings Per Share (EPS TTM) of Biogen Inc (BIIB)?
The Earnings Per Share (EPS TTM) of Biogen Inc (BIIB) is 8.83.